Cargando…

Identification of immunotherapy-related lncRNA signature for predicting prognosis, immunotherapy responses and drug candidates in bladder cancer

BACKGROUND: Bladder cancer (BC) is one of the most common malignant diseases and the most common causes of cancer death worldwide. Immunotherapy has opened new avenues for precision treatment of bladder tumours, and immune checkpoint inhibitors (ICIs) have revolutionized the clinical treatment strat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hui, Pengyu, Ni, Feng, Zheng, Liang, Jia, Lei, Wang, Zhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111848/ https://www.ncbi.nlm.nih.gov/pubmed/37072750 http://dx.doi.org/10.1186/s12885-023-10828-z

Ejemplares similares

Identification and Application of a Novel Immune-Related lncRNA Signature on the Prognosis and Immunotherapy for Lung Adenocarcinoma
por: Zeng, Zhimin, et al.
Publicado: (2022)

Identification of a glutamine metabolism reprogramming signature for predicting prognosis, immunotherapy efficacy, and drug candidates in bladder cancer
por: Xu, Yan, et al.
Publicado: (2023)

Identification and Characterization of an Ageing-Associated 13-lncRNA Signature That Predicts Prognosis and Immunotherapy in Hepatocellular Carcinoma
por: Li, Fulei, et al.
Publicado: (2023)

Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma
por: Xue, Ling, et al.
Publicado: (2021)

Ferroptosis-related lncRNA signature predicts prognosis and immunotherapy efficacy in cutaneous melanoma
por: Xu, Yujian, et al.
Publicado: (2022)

Significance of cuproptosis‐related lncRNA signature in LUAD prognosis and immunotherapy: A machine learning approach
por: Yang, Lihong, et al.
Publicado: (2023)

Identification of CD4(+) Conventional T Cells-Related lncRNA Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Breast Cancer
por: Ning, Shipeng, et al.
Publicado: (2022)

Development of a novel angiogenesis-related lncRNA signature to predict the prognosis and immunotherapy of glioblastoma multiforme
por: Zhang, Binbin, et al.
Publicado: (2022)

A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma
por: Yu, Sheng, et al.
Publicado: (2023)

Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma
por: Li, Lili, et al.
Publicado: (2021)

Identification of a apoptosis-related LncRNA signature to improve prognosis prediction and immunotherapy response in lung adenocarcinoma patients
por: Luo, Ting, et al.
Publicado: (2022)

Identification and validation of a five-lncRNA signature for predicting survival with targeted drug candidates in ovarian cancer
por: Lin, Nuan, et al.
Publicado: (2021)

The LncRNA signature associated with cuproptosis as a novel biomarker of prognosis in immunotherapy and drug screening for clear cell renal cell carcinoma
por: Zhang, Lishuo, et al.
Publicado: (2023)

Senescence-Related lncRNA Signature Predicts Prognosis, Response to Immunotherapy and Chemotherapy in Skin Cutaneous Melanoma
por: Lin, Kefan, et al.
Publicado: (2023)

Identification of pyroptosis-related lncRNA subtype and signature predicts the prognosis in bladder cancer
por: Zeng, Tao, et al.
Publicado: (2023)

Identification and validation of a novel cuproptosis-related lncRNA signature for prognosis and immunotherapy of head and neck squamous cell carcinoma
por: Xu, Qiu-Shuang, et al.
Publicado: (2022)

A potential biological signature of 7-methylguanosine-related lncRNA to predict the immunotherapy effects in bladder cancer
por: Xie, Shangxun, et al.
Publicado: (2023)

A Novel Nine-lncRNA Risk Signature Correlates With Immunotherapy in Hepatocellular Carcinoma
por: Nie, Ye, et al.
Publicado: (2021)

Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer
por: Chen, Erbao, et al.
Publicado: (2022)

Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning
por: Bai, Zhixun, et al.
Publicado: (2022)

Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma
por: Zhang, Hongpan, et al.
Publicado: (2022)

Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer
por: Zhang, Lianghao, et al.
Publicado: (2021)

Identification of cuproptosis‐related lncRNAs for prognosis and immunotherapy in glioma
por: Wang, Lin, et al.
Publicado: (2022)

Development of a novel hypoxia-immune–related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer
por: Luan, Likun, et al.
Publicado: (2022)

Identification and validation of a novel cuproptosis-related lncRNA gene signature to predict prognosis and immune response in bladder cancer
por: Chen, Jia, et al.
Publicado: (2022)

Identification and validation of a novel signature for prediction the prognosis and immunotherapy benefit in bladder cancer
por: Zhang, Yichi, et al.
Publicado: (2022)

Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer
por: Wang, Yejinpeng, et al.
Publicado: (2020)

Machine learning-based construction of a ferroptosis and necroptosis associated lncRNA signature for predicting prognosis and immunotherapy response in hepatocellular cancer
por: Zhao, Lei, et al.
Publicado: (2023)

Prognostic pyroptosis-related lncRNA signature predicts the efficacy of immunotherapy in hepatocellular carcinoma
por: Cheng, Zina, et al.
Publicado: (2022)

Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma
por: Pang, Yipeng, et al.
Publicado: (2023)

Identifying immune checkpoint-related lncRNA biomarkers for immunotherapy response and prognosis in cancers
por: Gao, Yue, et al.
Publicado: (2023)

Identification of tumor microenvironment-related signature for predicting prognosis and immunotherapy response in patients with bladder cancer
por: Yao, Zhihao, et al.
Publicado: (2022)

A New Ferroptosis-Related lncRNA Signature Predicts the Prognosis of Bladder Cancer Patients
por: Chen, Mei, et al.
Publicado: (2021)

Identification of genomic instability related lncRNA signature with prognostic value and its role in cancer immunotherapy in pancreatic cancer
por: Zhu, Xiaole, et al.
Publicado: (2022)

Construction of an m6A-related lncRNA model for predicting prognosis and immunotherapy in patients with lung adenocarcinoma
por: Shen, Hong-Yu, et al.
Publicado: (2023)

LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy
por: Li, Gaopeng, et al.
Publicado: (2021)

LncRNA and its role in gastric cancer immunotherapy
por: Zhang, Qiang, et al.
Publicado: (2023)

Role of a Pyroptosis-Related lncRNA Signature in Risk Stratification and Immunotherapy of Ovarian Cancer
por: Zhang, Zeyu, et al.
Publicado: (2022)

Identification of the 11-lncRNA signatures associated with the prognosis of endometrial carcinoma
por: Wan, Jing, et al.
Publicado: (2021)

Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma
por: Tang, Yuqin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_f1q4pkh67kiohvicaqbk86iv95